Company Filing History:
6 out of 4,446 
2 out of 1,289 
Years Active: 2006-2019
Title: Gerd Ruehter: Innovator in Psychiatric Treatment
Introduction
Gerd Ruehter is a notable inventor based in Hamburg, Germany. He has made significant contributions to the field of psychiatric treatment through his innovative research and development. With a total of 8 patents to his name, Ruehter has focused on creating compounds that address psychiatric disorders and neurodegenerative diseases.
Latest Patents
Among his latest patents are the "Selective FKBP51 ligands for treatment of psychiatric disorders." This invention relates to compounds that possess a selective FKBP51 ligand scaffold, along with their pharmaceutically acceptable salts. These compounds are designed for use in pharmaceutical compositions that can be combined with acceptable carriers, excipients, or diluents. The selective FKBP51 ligand compounds are intended for the prophylaxis and treatment of psychiatric disorders and neurodegenerative conditions.
Career Highlights
Throughout his career, Gerd Ruehter has worked with prominent organizations, including Eli Lilly and Company and the Max Planck Society for the Advancement of Science. His work in these institutions has allowed him to collaborate with leading experts in the field, further enhancing his contributions to psychiatric research.
Collaborations
Some of his notable coworkers include Jolie Anne Bastian and Daniel Jon Sall. Their collaborative efforts have played a crucial role in advancing the research and development of psychiatric treatments.
Conclusion
Gerd Ruehter's innovative work in developing selective FKBP51 ligands marks a significant advancement in the treatment of psychiatric disorders. His contributions continue to influence the field and offer hope for improved therapeutic options.